CD79

• Next message: Marty Bigos: "Re: password software again"
• Previous message: joan Kalnitsky: "Glut-4"
• Messages sorted by: [ date ] [ thread ] [ subject ] [ author ]

Hello Everyone,

Presently, in our screening panel for B cell malignancies, we are using
CD19,  CD20, and CD38 mABs to recognize the B cell at any stage of its
development.

Recently, most of the literature that addresses B cells includes CD79
in its phenotype. Is there an advantage in using anti-CD79 over one of
the previously mentioned antibodies or perhaps in conjunction with the
others? Does this antibody provide any novel information not provided by
the others? Also, is it expressed on the surface or cytoplasmically in
early B cell development?

Respectfully submitted,

Sabina Sylvest

• Next message: Marty Bigos: "Re: password software again"
• Previous message: joan Kalnitsky: "Glut-4"
• Messages sorted by: [ date ] [ thread ] [ subject ] [ author ]

This archive was generated by hypermail 2b29 : Sun Jan 05 2003 - 19:26:26 EST